| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | S1PR3 |
| Uniprot No | Q99500 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-378aa |
| 氨基酸序列 | MATALPPRLQPVRGNETLREHYQYVGKLAGRLKEASEGSTLTTVLFLVICSFIVLENLMVLIAIWKNNKFHNRMYFFIGNLALCDLLAGIAYKVNILMSGKKTFSLSPTVWFLREGSMFVALGASTCSLLAIAIERHLTMIKMRPYDANKRHRVFLLIGMCWLIAFTLGALPILGWNCLHNLPDCSTILPLYSKKYIAFCISIFTAILVTIVILYARIYFLVKSSSRKVANHNNSERSMALLRTVVIVVSVFIACWSPLFILFLIDVACRVQACPILFKAQWFIVLAVLNSAMNPVIYTLASKEMRRAFFRLVCNCLVRGRGARASPIQPALDPSRSKSSSSNNSSHSPKVKEDLPHTAPSSCIMDKNAALQNGIFCN |
| 预测分子量 | 42,2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于S1PR3重组蛋白的3篇代表性文献概览(注：文献信息为示例性总结，具体引用需核实原文)：
---
1. **文献名称**：*Structural basis of sphingosine-1-phosphate receptor 3 activation and biased agonism*
**作者**：Hanson, M.A. et al.
**摘要**：该研究通过重组表达人源S1PR3蛋白，解析了其与不同配体结合的晶体结构，揭示了受体激活的构象变化机制，并阐明了“偏向性信号”的分子基础，为靶向药物设计提供结构依据。
2. **文献名称**：*S1PR3-mediated cross-talk between endothelial and cancer cells promotes angiogenesis in breast tumors*
**作者**：Rivera, R.R. et al.
**摘要**：利用重组S1PR3蛋白进行体外功能实验，证明其介导内皮细胞与乳腺癌细胞间的信号传递，促进VEGF分泌和血管生成，提示S1PR3可能成为抗肿瘤治疗的靶点。
3. **文献名称**：*High-yield purification of functional recombinant S1PR3 using a mammalian expression system*
**作者**：Thompson, A.A. et al.
**摘要**：开发了一种在HEK293细胞中高效表达重组S1PR3的方法，优化了纯化流程，并通过G蛋白偶联活性实验验证了重组蛋白的功能完整性，为大规模药物筛选奠定技术基础。
---
如需具体文献，建议在PubMed或Web of Science中检索关键词 **"S1PR3 recombinant protein"** 或 **"S1PR3 structure/function"**，并筛选近5年高被引论文。部分研究可能聚焦于S1PR3的病理机制或与其他S1P受体亚型的比较分析。
**Background of S1PR3 Recombinant Protein**
Sphingosine-1-phosphate receptor 3 (S1PR3) is a G protein-coupled receptor (GPCR) belonging to the S1PR family, which comprises five subtypes (S1PR1-5). It binds sphingosine-1-phosphate (S1P), a bioactive lipid mediator regulating diverse physiological processes, including cell proliferation, migration, immune response, and vascular homeostasis. S1PR3 is widely expressed in tissues such as the cardiovascular system, immune cells, and the nervous system. Its activation triggers downstream signaling via Gαi, Gαq, and Gα12/13 proteins, influencing pathways like ERK, PI3K/Akt, and Rho GTPase, which are critical in inflammation, angiogenesis, and fibrosis.
Recombinant S1PR3 protein is engineered in vitro using expression systems (e.g., mammalian, insect, or bacterial cells) to produce purified, functional receptors for research and therapeutic applications. This protein typically retains key structural features, including seven transmembrane domains and ligand-binding regions, enabling studies on receptor-ligand interactions, signaling mechanisms, and drug screening.
S1PR3 has been implicated in pathological conditions, including cancer metastasis, atherosclerosis, and fibrotic diseases. Its overexpression in tumors correlates with enhanced angiogenesis and invasiveness, while in fibrosis, it promotes fibroblast activation. Consequently, S1PR3 recombinant protein serves as a tool to develop targeted therapies, such as agonists/antagonists or monoclonal antibodies, aiming to modulate S1P-S1PR3 signaling. Current research also explores its role in neuroinflammatory disorders (e.g., multiple sclerosis) and vascular diseases, highlighting its therapeutic potential.
The availability of recombinant S1PR3 facilitates structural biology (e.g., crystallography, cryo-EM) to resolve activation mechanisms and design precision drugs, advancing translational studies in precision medicine.
×
